Business Context and Reporting Period
This Form 8-K, dated February 9, 2026, reports on Thermo Fisher Scientific Inc.'s entry into a material definitive agreement to issue new senior notes. The filing details a public offering of debt securities completed on February 12, 2026, intended to finance the previously announced acquisition of Clario Holdings, Inc.
Key Financial Metrics and Debt Issuance
The Company issued a total of $3.8 billion in aggregate principal amount of Senior Notes across four tranches:
- 2031 Notes: $1.0 billion at 4.215% interest, maturing February 12, 2031.
- 2033 Notes: $750 million at 4.550% interest, maturing June 15, 2033.
- 2036 Notes: $1.3 billion at 4.902% interest, maturing February 12, 2036.
- 2046 Notes: $750 million at 5.546% interest, maturing February 12, 2046.
Net Proceeds: Approximately $3.76 billion after deducting underwriting discounts and estimated offering expenses.
Use of Proceeds: Primarily to pay a portion of the cash consideration for the Clario Acquisition. Pending completion, funds may be used for general corporate purposes, debt refinancing, or temporary short-term investments.
Liquidity and Capital Structure: The Notes are general unsecured obligations ranking equally with existing unsecured debt and senior to subordinated debt. They are effectively subordinated to future secured indebtedness and structurally subordinated to subsidiary liabilities.
Material Changes and Covenants
This filing represents a significant increase in the Company's long-term debt obligations. The Indenture includes limited affirmative and negative covenants, specifically restricting:
- Incurrence of debt secured by liens on Principal Properties.
- Engagement in sale and lease-back transactions regarding Principal Properties.
- Mergers, consolidations, or sales of substantially all assets.
Redemption Terms: The Company may redeem notes prior to specific "Par Call Dates" at a price equal to the greater of 100% of principal or the present value of remaining payments discounted at the Treasury Rate plus a spread (ranging from 10 to 15 basis points). After the Par Call Dates, notes may be redeemed at 100% of principal plus accrued interest.
Change of Control: Upon a change of control and a contemporaneous downgrade below investment grade by at least two rating agencies, the Company must offer to repurchase the Notes at 101% of principal plus accrued interest.
Guidance, Risks, and Contingencies
Acquisition Contingency: The use of proceeds for the Clario Acquisition is subject to customary closing conditions, including regulatory approvals. If the acquisition does not close, proceeds may be redirected to general corporate purposes.
Risk Factors: The filing references risks related to capital market conditions, the completion of the Offering, and the Clario Acquisition. Forward-looking statements are subject to uncertainties that could cause actual results to differ materially from expectations.
Events of Default: Includes payment defaults, covenant breaches, bankruptcy, insolvency, and failure to pay certain indebtedness, which could trigger acceleration of the entire principal amount.
Investor Verification Checklist
- Verify the final closing status and regulatory approval of the Clario Acquisition to confirm the ultimate use of proceeds.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Supplemental Indenture (Exhibit 4.2) for detailed covenant restrictions.
- Monitor credit rating actions by Moody's, S&P, and Fitch, as a downgrade below investment grade could trigger a mandatory repurchase offer.
- Assess the impact of the new interest rate obligations (ranging from 4.215% to 5.546%) on the Company's future interest coverage ratios.
- Confirm the timing of the first interest payment dates (August 12, 2026, for most tranches; June 15, 2026, for 2033 Notes).